Tirzepatide affects sleep in two very different ways. For people with obesity and sleep apnea, it is the first drug approved to treat the condition, and in trials it cut breathing interruptions by 25 to 29 events per hour. For everyone else, the label lists fatigue as a common side effect but does not list insomnia, night sweats or vivid dreams. This page covers both halves. If you are new to the drug, start with our tirzepatide guide.
Key takeaways
- Zepbound (tirzepatide) was approved on December 20, 2024 for moderate to severe obstructive sleep apnea in adults with obesity.
- In SURMOUNT-OSA, the apnea-hypopnea index fell by 25.3 events per hour (not on PAP) and 29.3 (on PAP) over 52 weeks, versus 5.3 and 5.5 with placebo.
- Mounjaro contains the same drug but is labeled for type 2 diabetes only, and compounded tirzepatide is not FDA approved for sleep apnea or any other use.
- The Zepbound label lists fatigue among the most common adverse reactions. It does not list insomnia, night sweats or vivid dreams.
- The label says you can inject any time of day, with or without food, so timing is one lever you can discuss with your prescriber if sleep changes.
How does tirzepatide help sleep apnea?
Obstructive sleep apnea (OSA) happens when the upper airway narrows or closes over and over during sleep. Breathing pauses or gets shallow, oxygen dips, and sleep is broken. The National Heart, Lung, and Blood Institute lists excess weight as a risk factor, because extra tissue around the throat makes the airway more likely to collapse.
Tirzepatide acts on two gut hormone receptors, GIP and GLP-1. It lowers appetite and slows how fast the stomach empties, and people lose a lot of weight. In the sleep apnea trials, that weight loss came with a large drop in breathing interruptions. The trials measured the result, not the exact mechanism, so weight loss is the most likely explanation and the only one this page will claim.
Tirzepatide for OSA: the SURMOUNT-OSA results
SURMOUNT-OSA is the program behind the approval. It enrolled adults with obesity and moderate to severe OSA and ran two 52-week trials side by side. Trial 1 was in people not using positive airway pressure (PAP) therapy. Trial 2 was in people who were using PAP. Each compared tirzepatide with placebo.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →| SURMOUNT-OSA outcome at 52 weeks | Trial 1 (not on PAP): tirzepatide | Trial 1: placebo | Trial 2 (on PAP): tirzepatide | Trial 2: placebo |
|---|---|---|---|---|
| Change in apnea-hypopnea index (events per hour) | -25.3 | -5.3 | -29.3 | -5.5 |
| Change in body weight | -17.7% | -1.6% | -19.6% | -2.3% |
Source: SURMOUNT-OSA, Malhotra et al., NEJM 2024; ClinicalTrials.gov NCT05412004.
Both trials point the same way. People on tirzepatide had 25 to 29 fewer breathing interruptions per hour, whether or not they were using PAP, and lost roughly 18% to 20% of their body weight. The trial on PAP still showed the benefit on top of the device, and the label does not tell anyone to stop PAP.
What AHI means
The apnea-hypopnea index, or AHI, is the score a sleep study produces. It counts apneas (full pauses in breathing) and hypopneas (partial drops in airflow) per hour of sleep. A higher AHI means more interruptions and more severe OSA. When a trial reports a fall of 25 events per hour, that is 25 fewer interruptions in every hour of sleep. The Zepbound label uses the words "moderate to severe" for the OSA it covers. Where you fall on that scale comes from a sleep study, which is why a sleep study is the first step, not the injection.
Mounjaro OSA, Zepbound OSA: which label covers it
Zepbound is the brand with the sleep apnea indication. Its label covers adults with obesity and moderate to severe OSA, used with a reduced-calorie diet and increased physical activity. Mounjaro contains the same drug but its label covers type 2 diabetes only; a Mounjaro prescription written for sleep apnea is off-label. The dosing is the same for either brand: 2.5 mg once weekly for 4 weeks, then 2.5 mg steps after at least 4 weeks on each dose, with maintenance doses of 5, 10 or 15 mg. For the two labels side by side, read is Mounjaro approved for sleep apnea. For the trial in more depth, see Zepbound for sleep apnea.
Tirzepatide sleep issues: what the label lists and does not list
Now the other half. Some people start tirzepatide and find their sleep changes. Before guessing at causes, it helps to know what the prescribing information actually records.
| Sleep-related complaint | On the Zepbound label's most common adverse reactions list? | What that means |
|---|---|---|
| Fatigue (tiredness) | Yes | Fatigue was reported by at least 5% of Zepbound trial participants and more often than with placebo. |
| Insomnia (trouble falling or staying asleep) | No | The label does not list insomnia among common adverse reactions and gives no rate for it. |
| Night sweats | No | The label does not list night sweats and gives no rate for them. |
| Vivid dreams or nightmares | No | The label does not list vivid dreams and gives no rate for them. |
| Nausea, reflux, burping, abdominal pain | Yes | All are listed. Any of them can wake you if they happen at night. |
Source: Zepbound prescribing information (DailyMed), adverse reactions section.
So the label supports one thing directly: feeling tired is a recognized, common effect. For insomnia, night sweats and vivid dreams, the label is silent. That does not mean nobody experiences them. It means no trial number exists for them, so this page does not print one. What follows are plausible explanations, each framed as a possibility to check, not a proven cause.
Tirzepatide insomnia: possible reasons sleep gets worse
- Nausea or reflux at night. Nausea, gastroesophageal reflux disease and burping are all on the label. Lying flat after a meal can make reflux worse, and discomfort can keep you awake or wake you up.
- Eating too little. The drug blunts appetite. If you skip dinner or eat very little all day, hunger or low energy can surface at night.
- Dehydration. The label warns that vomiting or diarrhea can lead to fluid loss and, in serious cases, kidney injury. Even mild dehydration can bring headaches, cramps and restless sleep.
- Low blood sugar with insulin or a sulfonylurea. The label warns that tirzepatide raises the risk of hypoglycemia when taken with insulin or an insulin secretagogue (such as a sulfonylurea). Low blood sugar overnight can cause waking, sweating and a racing heart. If you take either drug class, talk to your prescriber; the label says a dose reduction of those drugs may be needed.
- Caffeine. Coffee or tea that used to be fine on a full stomach may hit harder when you are eating less.
- A new routine. Weekly injections, new eating habits and weight loss itself all change your day. Sleep often takes time to settle into a new pattern.
Tirzepatide night sweats
Night sweats are not on the label. If they happen, the two most useful questions are whether you take insulin or a sulfonylurea (low blood sugar can cause sweating), and whether you are dehydrated or feverish for another reason. Sweating with a fever, a rash or swelling is a reason to call your prescriber the same day, because the label also lists hypersensitivity reactions. Sweating that comes with chest discomfort or a very fast heartbeat should be treated as urgent.
Tirzepatide vivid dreams
Vivid dreams are not on the label, and the trials did not report on dream content. Broken sleep from nausea, reflux, or waking to use the bathroom can make people remember dreams they would normally sleep through. Going to bed on an empty stomach, or on a very full one, can do the same. If dreams are distressing, mention them at your next visit. Any change in mood or sleep is worth saying out loud.
Does tirzepatide affect sleep? Practical steps
None of these steps changes your dose. Dose decisions belong to your prescriber.
| Possible cause | Step you can take | What the label says |
|---|---|---|
| Nausea or reflux at night | Eat your last meal earlier and keep it small. Avoid lying down right after eating. | Nausea, reflux and burping are common adverse reactions. |
| Injection day falls badly | Ask your prescriber about moving the day or the time of day. | Inject any time of day, with or without meals. The day can change if at least 3 days (72 hours) separate two doses. |
| Eating too little | Aim for regular, modest meals with protein even when you are not hungry. | The label pairs the drug with a reduced-calorie diet, not with skipping meals. |
| Dehydration | Drink fluids through the day, more if you have vomiting or diarrhea. | Fluid loss from GI effects can lead to acute kidney injury. |
| Low blood sugar overnight | If you take insulin or a sulfonylurea, tell your prescriber about night waking or sweats. | Hypoglycemia risk rises with insulin or insulin secretagogues; their dose may need to be reduced. |
| Caffeine or a new routine | Cut caffeine after midday and keep a fixed wake time for a couple of weeks. | Not addressed by the label. |
Source: Zepbound and Mounjaro prescribing information (DailyMed), dosage and administration, warnings and precautions, and drug interactions sections.
If sleep problems last more than a few weeks, or come with mood changes, severe stomach pain, or signs of dehydration, talk to your prescriber rather than waiting them out. Fatigue that does not improve is also worth a conversation; see does tirzepatide make you tired for that side of the question, and the tirzepatide side effects guide for the full label list.
What this means for compounded tirzepatide
Everything above comes from the branded product. Compounded tirzepatide is not FDA approved for sleep apnea or for any other use, has no sleep apnea trial of its own, and is not interchangeable with Zepbound or Mounjaro. The side-effect list on the label is still the best guide to what to expect from the molecule, and the practical steps above apply the same way. A licensed provider decides whether a compounded medication is appropriate for you. If you have diagnosed sleep apnea, tell that provider and keep your sleep clinician informed. FormBlends pricing does not change with dose; see pricing or begin the assessment.
Frequently Asked Questions
How does tirzepatide help sleep apnea?
In SURMOUNT-OSA, tirzepatide cut the apnea-hypopnea index by 25.3 to 29.3 events per hour over 52 weeks, alongside 17.7% to 19.6% weight loss. Excess weight narrows the airway, so weight loss is the most likely reason. The trials did not measure any other mechanism.
Does tirzepatide cause insomnia?
The Zepbound label does not list insomnia among common adverse reactions, so there is no trial number for it. Night-time nausea or reflux, eating too little, dehydration, caffeine, or low blood sugar with insulin or a sulfonylurea are plausible reasons sleep can suffer. Talk to your prescriber if it lasts.
Does tirzepatide cause night sweats?
Night sweats are not on the label. If you take insulin or a sulfonylurea, low blood sugar overnight is one possibility the label's hypoglycemia warning points to. Sweats with fever, rash, swelling or chest symptoms need a same-day call.
Does tirzepatide cause vivid dreams?
Vivid dreams are not on the label and were not reported in the trials. Broken sleep from stomach symptoms can make dreams easier to remember. Mention distressing dreams or mood changes to your prescriber.
Does tirzepatide affect sleep?
Yes, in two directions. It improves sleep apnea in adults with obesity, and it can bring fatigue, which is on the label. Other sleep complaints are not listed on the label, so treat them as something to investigate with your prescriber rather than a known effect.
Is Mounjaro approved for OSA?
No. Zepbound carries the sleep apnea indication, approved December 20, 2024. Mounjaro contains the same drug, tirzepatide, but is labeled for type 2 diabetes only.
Sources
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA), Malhotra et al., New England Journal of Medicine, 2024.
- SURMOUNT-OSA study record (NCT05412004), ClinicalTrials.gov.
- FDA Approves First Medication for Obstructive Sleep Apnea, U.S. Food and Drug Administration, December 20, 2024.
- Zepbound (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
- Mounjaro (tirzepatide) prescribing information, DailyMed, National Library of Medicine, revised 08/2026.
- Sleep Apnea, National Heart, Lung, and Blood Institute.
Next steps
Browse the tirzepatide hub for every other tirzepatide question. Talk to a clinician about any sleep change that lasts, and keep your sleep specialist involved if you have sleep apnea. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; a licensed provider decides whether it is appropriate for you.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →